Kazia Therapeutics (KZIA) Net Cash Flow (2019 - 2022)

Kazia Therapeutics (KZIA) has 3 years of Net Cash Flow data on file, last reported at -$5.8 million in Q4 2022.

• In Q4 2022, Net Cash Flow changed N/A year-over-year to -$5.8 million; the TTM figure through Jun 2024 stood at -$5.8 million (changed 0.0% YoY), while the FY2025 annual figure was $1.7 million, up 173.07% from the prior year.
• Net Cash Flow improved to -$5.8 million in Q4 2022, from -$9.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at -$1.9 million in Q4 2019 and bottomed at -$9.0 million in Q4 2020.
• A 3-year average of -$5.5 million and a median of -$5.8 million in 2022 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 379.74% in 2020, down 379.74% in 2020.
• Year by year, Net Cash Flow stood at -$1.9 million in 2019, then sank by 379.74% to -$9.0 million in 2020, then soared by 35.48% to -$5.8 million in 2022.
• The last three Net Cash Flow figures came in at -$5.8 million (Q4 2022), -$9.0 million (Q4 2020), and -$1.9 million (Q4 2019), per Business Quant data.

Peer Comparison